3-[(2S,8R,9R)-11-(2-hydroxyethyl)-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfomamido]methyl}-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxaazacyclotetradecin-14-yl]-1-phenylurea | 1353557-56-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 3-[(2S,8R,9R)-11-(2-hydroxyethyl)-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfomamido]methyl}-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxaazacyclotetradecin-14-yl]-1-phenylurea
• 英文别名: 3-[(2S,8R,9R)-11-{2-[hydroxy]ethyl}-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfonamido]methyl}-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxazacyclotetradecin-14-yl]-1-phenylurea；1-[(3S,9R,10R)-9-[[(4-fluorophenyl)sulfonyl-methyl-amino]methyl]-12-(2-hydroxyethyl)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(18),14,16-trien-16-yl]-3-phenyl-urea；1-[(3S,9R,10R)-9-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-12-(2-hydroxyethyl)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea
• CAS: 1353557-56-8
• 化学式: C₃₄H₄₃FN₄O₇S
• 分子量: 670.802
• InChiKey: HWHPSEVMZHAVHD-NPPPIGHJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  47
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  3-[(2S,8R,9R)-11-[2-[(4-methoxyphenyl)methoxy]ethyl]-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfomamido]methyl}-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxaazacyclotetradecin-14-yl]-1-phenylurea 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以71%的产率得到3-[(2S,8R,9R)-11-(2-hydroxyethyl)-2,9-dimethyl-8-{[N-methyl(4-fluorobenzene)sulfomamido]methyl}-12-oxo-2,3,4,5,6,8,9,10,11,12-decahydro-1,7,11-benzodioxaazacyclotetradecin-14-yl]-1-phenylurea
  参考文献：
  名称：

  Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria

  摘要：

  Here, we describe the discovery of a novel antimalarial agent using phenotypic screening of Plasmodium falciparum asexual blood-stage parasites. Screening a novel compound collection created using diversity-oriented synthesis (DOS) led to the initial hit. Structure activity relationships guided the synthesis of compounds having improved potency and water solubility, yielding a subnanomolar inhibitor of parasite asexual blood-stage growth. Optimized compound 27 has an excellent off-target activity profile in erythrocyte lysis and HepG2 assays and is stable in human plasma. This compound is available via the molecular libraries probe production centers network (MLPCN) and is designated ML238.

  DOI：

  10.1021/ml200244k